MICALL2

Across TCGA pan-cancer cohorts, MICALL2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of MICALL2’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where MICALL2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MICALL2 is over-expressed in tumor.

PDAC, LUAD, and HNSC are the cancer types where MICALL2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MICALL2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	All	+0.875	<.001	9	view →
LUAD	Female	III,IV	+0.673	<.001	8	view →
HNSC	Male	IV	+0.495	<.001	8	view →
COAD	Male	All	+0.167	<.001	5	view →
CCRCC	All	All	+0.218	<.001	4	view →
LSCC	Female	All	+0.175	.018	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

MICALL2–PDAC

Open the PDAC breakdown →